Samuel Álvarez-Almazán

Dr. Samuel Álvarez-Almazán

Facultad de Estudios Superiores Cuautitlán, Cuautitlán Izcalli, México, Mexico
orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2016 in PPAR Research
Verified
Journal Article
Open access
PDF file
DAD. Alemán-González-Duhart
D. Alemán-González-Duhart
FTF. Tamay-Cach
F. Tamay-Cach
Samuel Álvarez-AlmazánSamuel Álvarez-Almazán
Samuel Álvarez-Almazán
JMJessica Elena Mendieta-Wejebe
Jessica Elena Mendieta-Wejebe
The present review summarizes the current advances in the biochemical and physiological aspects in the treatment of type 2 diabetes mellitus (DM2) with thiazolidinediones (TZDs). DM2 is a metabolic disorder characterized by hyperglycemia, triggering the abnormal activation of physiological pathways such as glucose autooxidation, polyol’s pathway, formation of advance glycation end (AGE) products, and glycolysis, leading to the overproduction of reactive oxygen species (ROS) and proinflammatory cytokines, which are responsible for the micro- and macrovascular complications of the disease. The treatment of DM2 has been directed toward the reduction of hyperglycemia using different drugs such as insulin sensitizers, as the case of TZDs, which are able to lower blood glucose levels and circulating triglycerides by binding to the nuclear peroxisome proliferator-activated receptor gamma (PPARγ) as full agonists. When TZDs interact with PPARγ, the receptor regulates the transcription of different genes involved in glucose homeostasis, insulin resistance, and adipogenesis. However, TZDs exhibit some adverse effects such as fluid retention, weight gain, hepatotoxicity, plasma-volume expansion, hemodilution, edema, bone fractures, and congestive heart failure, which limits their use in DM2 patients.

13 June 2022 in Carbohydrate Polymer Technologies and Applications
Verified
Journal Article
Open access
MBMaría Eugenia Eugenia Aranda Barradas
María Eugenia Eugenia Aranda Barradas
STSaul E. Trejo-López
Saul E. Trejo-López
ARAlicia Del Real
Alicia Del Real
Samuel Álvarez-AlmazánSamuel Álvarez-Almazán
Samuel Álvarez-Almazán
AMAbraham Méndez-Albores
Abraham Méndez-Albores
SMSusana Patricia Miranda-Castro
Susana Patricia Miranda-Castro

1 February 2020 in Journal of Physiology and Biochemistry
Verified
Journal Article
Closed access
PDF file
Samuel Álvarez-AlmazánSamuel Álvarez-Almazán
Samuel Álvarez-Almazán
JFJessica Georgina Filisola-Villaseñor
Jessica Georgina Filisola-Villaseñor
DADiana Alemán
Diana Alemán
FTFeliciano Tamay-Cach
Feliciano Tamay-Cach
JMJessica Elena Mendieta-Wejebe
Jessica Elena Mendieta-Wejebe

1 October 2017 in Biochemical Pharmacology
Verified
Journal Article
Closed access
Samuel Álvarez-AlmazánSamuel Álvarez-Almazán
Samuel Álvarez-Almazán
MBMartiniano Bello
Martiniano Bello
FTFeliciano Tamay-Cach
Feliciano Tamay-Cach
MMMarlet Martínez-Archundia
Marlet Martínez-Archundia
DADiana Alemán-González-Duhart
Diana Alemán-González-Duhart
JMJessica Elena Mendieta-Wejebe
Jessica Elena Mendieta-Wejebe

Verified
Journal Article
Open access
PDF file
Samuel Álvarez-AlmazánSamuel Álvarez-Almazán
Samuel Álvarez-Almazán
LSLuz Cassandra Solís-Domínguez
Luz Cassandra Solís-Domínguez
PDPaulina Duperou
Paulina Duperou
TFTeresa Fuerte-Gómez
Teresa Fuerte-Gómez
Martín González-AndradeMartín González-Andrade
Martín González-Andrade
Francisco Cortes-BenitezFrancisco Cortes-Benitez
Francisco Cortes-Benitez
Type 2 diabetes (T2D) is one of the most common diseases and the 8th leading cause of death worldwide. Individuals with T2D are at risk for several health complications that reduce their life expectancy and quality of life. Although several drugs for treating T2D are currently available, many of them have reported side effects ranging from mild to severe. In this work, we present the synthesis in a gram-scale as well as the in silico and in vitro activity of two semisynthetic glycyrrhetinic acid (GA) derivatives (namely FC-114 and FC-122) against Protein Tyrosine Phosphatase 1B (PTP1B) and α-glucosidase enzymes. Furthermore, the in vitro cytotoxicity assay on Human Foreskin fibroblast and the in vivo acute oral toxicity was also conducted. The anti-diabetic activity was determined in streptozotocin-induced diabetic rats after oral administration with FC-114 or FC-122. Results showed that both GA derivatives have potent PTP1B inhibitory activity being FC-122, a dual PTP1B/α-glucosidase inhibitor that could increase insulin sensitivity and reduce intestinal glucose absorption. Molecular docking, molecular dynamics, and enzymatic kinetics studies revealed the inhibition mechanism of FC-122 against α-glucosidase. Both GA derivatives were safe and showed better anti-diabetic activity in vivo than the reference drug acarbose. Moreover, FC-114 improves insulin levels while decreasing LDL and total cholesterol levels without decreasing HDL cholesterol.

1 June 2017 in Regulatory Toxicology and Pharmacology
Verified
Journal Article
Closed access
DADiana Alemán
Diana Alemán
FTFeliciano Tamay-Cach
Feliciano Tamay-Cach
JCJosé Correa-Basurto
José Correa-Basurto
IPItzia I. Padilla-Martinez
Itzia I. Padilla-Martinez
Samuel Álvarez-AlmazánSamuel Álvarez-Almazán
Samuel Álvarez-Almazán
JMJessica Elena Mendieta-Wejebe
Jessica Elena Mendieta-Wejebe